Zhi Tong Cai Jing·2025-09-25 08:38Core Viewpoint - Shandong Xinhua Pharmaceutical has received approval from the National Medical Products Administration for the clinical trial of LXH-1211 tablets, aimed at treating pulmonary arterial hypertension [1] Company Summary - The clinical trial application for LXH-1211 tablets was accepted on July 10, 2025, and meets the requirements for drug registration [1] - LXH-1211 is a novel compound designed specifically for the clinical manifestations and pathological essence of pulmonary arterial hypertension [1] Mechanism of Action - LXH-1211 exhibits a dual mechanism of action: it stimulates soluble guanylate cyclase (sGC) to induce vasodilation and reduce pulmonary arterial hypertension, while also inhibiting AMP-activated protein kinase (AMPK) to prevent vascular remodeling and fibrosis [1] Clinical Indication - The proposed clinical indication for LXH-1211 is the treatment of pulmonary arterial hypertension [1]